GE Healthcare Invests in FISH Technologies for Leukemia and Lymphoma Testing GE Healthcare announced today that Clarient Diagnostic Service, Inc., a GE Healthcare company, has made significant upgrades to its fluorescence in situ hybridisation technologies to improve virtual analysis of testing results for a variety of blood diseases, including leukemia, lymphoma, myelodysplastic syndrome and myeloma.
March 4, 2014 - Business Wire via Yahoo! Finance